Sangamo BioSciences and Onyx Pharmaceuticals Announce Strategic Alliance To Develop Novel Cancer Therapeutics

Apr 05, 2001, 01:00 ET from Sangamo BioSciences, Inc.

    RICHMOND, Calif., April 5 /PRNewswire/ --
 Sangamo BioSciences, Inc. (Nasdaq:   SGMO) and
 Onyx Pharmaceuticals, Inc. (Nasdaq:   ONXX) today announced that the two
 companies will jointly research and develop novel cancer therapeutics using
 Sangamo's zinc finger DNA-binding protein transcription factor ("ZFP TF")
 technology platform and Onyx's selectively replicating adenovirus technology
 ("Therapeutic Viruses"). Under the terms of the agreement, the two companies
 will conduct studies using the combined technology platforms during an
 investigation period. When product candidates meet certain mutually determined
 criteria, the companies will equally share research and clinical development
 costs and jointly commercialize products resulting from the alliance.
     ZFP TFs are a class of naturally occurring transcription factors that can
 be engineered to bind to a precise sequence of DNA to permit the selective
 regulation of a specific gene. Though there are many kinds of transcription
 factors, only ZFP TFs are amenable to engineering and capable of targeting a
 particular gene or genes of interest. Sangamo's ZFP TF technology can be used
 to activate or repress virtually any gene.
     Onyx is developing a common cold virus (referred to as an adenovirus) that
 can effectively infect and kill cancer cells leaving normal cells unaffected.
 Onyx is also testing Therapeutic Viruses capable of delivering a therapeutic
 payload, such as an engineered ZFP TF, into cells. Under this alliance, Onyx's
 Therapeutic Virus will be engineered to deliver a ZFP TF, whose protein
 product has been shown to augment anti-tumor immune responses, thereby
 creating an Armed Therapeutic Virus(TM).
     "By combining our technologies, we hope to create an Armed Therapeutic
 Virus(TM) capable of treating the disease both at the tumor site and
 systemically," said Hollings Renton, Onyx's chairman and chief executive
 officer. "The resulting therapeutic will have the potential to be extremely
 specific, while at the same time allowing treatment of cancer throughout the
 body after systemic administration of the virus."
     "The ability to provoke an anti-tumor immune response and treat metastatic
 cancer would be a significant improvement over existing approaches, and
 together with Onyx, we have the potential to create such a product," said
 Edward Lanphier, Sangamo's president and chief executive officer. "This
 alliance further supports the potential of our ZFP TF technology to be applied
 in multiple commercially important markets, including its direct use as a
 human therapeutic."
 
     About Sangamo
     Sangamo is focused on the research and development of novel transcription
 factors for the regulation of gene expression. Sangamo's Universal Gene
 Recognition(TM) technology enables the engineering of a particular class of
 transcription factors known as zinc finger DNA-binding proteins, or ZFPs. By
 engineering ZFPs so that they can recognize a specific gene, Sangamo has
 created ZFP transcription factors that can control gene expression and,
 consequently, cell function. The company intends to establish Universal Gene
 Recognition as a widely used technology for commercial applications in
 pharmaceutical discovery, human therapeutics, clinical diagnostics,
 agriculture and industrial biotechnology. Over twenty leading pharmaceutical
 and biotechnology companies have utilized ZFP transcription factors. In
 addition, Sangamo is developing novel ZFP-based therapeutics for the treatment
 of cardiovascular disease. For more information about Sangamo, visit the
 company's web site at www.sangamo.com.
 
     About Onyx
     Onyx Pharmaceuticals is engaged in the discovery and development of novel
 cancer therapies. Based on its proprietary virus technologies, the company is
 developing its lead product, CI-1042 (ONYX-015). CI-1042 is currently in a
 Phase III clinical trial for head and neck cancer and in Phase I and II
 clinical trials for a number of different additional cancer indications. For
 more information about CI-1042 and Onyx's pipeline and activities, visit
 Onyx's web site at www.onyx-pharm.com.
     This press release contains forward-looking information within the meaning
 of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
 Exchange Act of 1934, and is subject to the safe harbors created by those
 sections. Those forward-looking statements include statements related to the
 ability of Sangamo BioSciences, Inc. to continue to meet marketing,
 technology, and customer demands as they relate to its products within the
 gene regulation market. The development of potential human therapeutic
 products also involve a number of risks and uncertainties, including but not
 limited to the timeline for clinical activity, results of pending or future
 clinical trials and changes in the status of the companies' collaborative
 relationships. Actual results may differ materially due to a number of
 factors, including numerous technological, operational and financial
 challenges associated with the regulation of genes. The matters discussed in
 this press release also involve risks and uncertainties discussed in the
 companies' filings with the Securities and Exchange Commission (SEC). In
 particular, see the risk factors described in these filings including the
 companies' most recent Annual Reports on Form 10-K and 10-Q. The companies
 assume no obligation to update the forward-looking information contained in
 this press release.
 
 

SOURCE Sangamo BioSciences, Inc.
    RICHMOND, Calif., April 5 /PRNewswire/ --
 Sangamo BioSciences, Inc. (Nasdaq:   SGMO) and
 Onyx Pharmaceuticals, Inc. (Nasdaq:   ONXX) today announced that the two
 companies will jointly research and develop novel cancer therapeutics using
 Sangamo's zinc finger DNA-binding protein transcription factor ("ZFP TF")
 technology platform and Onyx's selectively replicating adenovirus technology
 ("Therapeutic Viruses"). Under the terms of the agreement, the two companies
 will conduct studies using the combined technology platforms during an
 investigation period. When product candidates meet certain mutually determined
 criteria, the companies will equally share research and clinical development
 costs and jointly commercialize products resulting from the alliance.
     ZFP TFs are a class of naturally occurring transcription factors that can
 be engineered to bind to a precise sequence of DNA to permit the selective
 regulation of a specific gene. Though there are many kinds of transcription
 factors, only ZFP TFs are amenable to engineering and capable of targeting a
 particular gene or genes of interest. Sangamo's ZFP TF technology can be used
 to activate or repress virtually any gene.
     Onyx is developing a common cold virus (referred to as an adenovirus) that
 can effectively infect and kill cancer cells leaving normal cells unaffected.
 Onyx is also testing Therapeutic Viruses capable of delivering a therapeutic
 payload, such as an engineered ZFP TF, into cells. Under this alliance, Onyx's
 Therapeutic Virus will be engineered to deliver a ZFP TF, whose protein
 product has been shown to augment anti-tumor immune responses, thereby
 creating an Armed Therapeutic Virus(TM).
     "By combining our technologies, we hope to create an Armed Therapeutic
 Virus(TM) capable of treating the disease both at the tumor site and
 systemically," said Hollings Renton, Onyx's chairman and chief executive
 officer. "The resulting therapeutic will have the potential to be extremely
 specific, while at the same time allowing treatment of cancer throughout the
 body after systemic administration of the virus."
     "The ability to provoke an anti-tumor immune response and treat metastatic
 cancer would be a significant improvement over existing approaches, and
 together with Onyx, we have the potential to create such a product," said
 Edward Lanphier, Sangamo's president and chief executive officer. "This
 alliance further supports the potential of our ZFP TF technology to be applied
 in multiple commercially important markets, including its direct use as a
 human therapeutic."
 
     About Sangamo
     Sangamo is focused on the research and development of novel transcription
 factors for the regulation of gene expression. Sangamo's Universal Gene
 Recognition(TM) technology enables the engineering of a particular class of
 transcription factors known as zinc finger DNA-binding proteins, or ZFPs. By
 engineering ZFPs so that they can recognize a specific gene, Sangamo has
 created ZFP transcription factors that can control gene expression and,
 consequently, cell function. The company intends to establish Universal Gene
 Recognition as a widely used technology for commercial applications in
 pharmaceutical discovery, human therapeutics, clinical diagnostics,
 agriculture and industrial biotechnology. Over twenty leading pharmaceutical
 and biotechnology companies have utilized ZFP transcription factors. In
 addition, Sangamo is developing novel ZFP-based therapeutics for the treatment
 of cardiovascular disease. For more information about Sangamo, visit the
 company's web site at www.sangamo.com.
 
     About Onyx
     Onyx Pharmaceuticals is engaged in the discovery and development of novel
 cancer therapies. Based on its proprietary virus technologies, the company is
 developing its lead product, CI-1042 (ONYX-015). CI-1042 is currently in a
 Phase III clinical trial for head and neck cancer and in Phase I and II
 clinical trials for a number of different additional cancer indications. For
 more information about CI-1042 and Onyx's pipeline and activities, visit
 Onyx's web site at www.onyx-pharm.com.
     This press release contains forward-looking information within the meaning
 of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
 Exchange Act of 1934, and is subject to the safe harbors created by those
 sections. Those forward-looking statements include statements related to the
 ability of Sangamo BioSciences, Inc. to continue to meet marketing,
 technology, and customer demands as they relate to its products within the
 gene regulation market. The development of potential human therapeutic
 products also involve a number of risks and uncertainties, including but not
 limited to the timeline for clinical activity, results of pending or future
 clinical trials and changes in the status of the companies' collaborative
 relationships. Actual results may differ materially due to a number of
 factors, including numerous technological, operational and financial
 challenges associated with the regulation of genes. The matters discussed in
 this press release also involve risks and uncertainties discussed in the
 companies' filings with the Securities and Exchange Commission (SEC). In
 particular, see the risk factors described in these filings including the
 companies' most recent Annual Reports on Form 10-K and 10-Q. The companies
 assume no obligation to update the forward-looking information contained in
 this press release.
 
 SOURCE  Sangamo BioSciences, Inc.